Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease
Hongyan Liu(Jinan City People's Hospital), David Z.I. Cherney(University Health Network), Abid Ali Khan(University of Peshawar), Atit Dharia(University Health Network), Jacinthe Boulet(Montreal Heart Institute), Vikas S. Sridhar(University Health Network), Patrick R. Lawler(McGill University Health Centre)
Cited by 80
Related Papers
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
|The Lancet|2022|969
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19
|JAMA|2020|884
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.
|Bristol Research (University of Bristol)|2021|589
Molecular Basis for the Regulation of Angiogenesis by Thrombospondin-1 and -2
|Cold Spring Harbor Perspectives in Medicine|2012|546
Sodium Glucose Cotransporter-2 Inhibition in Heart Failure
|Circulation|2017|459